Biotech | September 29, 2025
DINAMIQS inaugurates new cGMP viral vector manufacturing facility in Switzerland
The new site enables end-to-end production of viral vector gene therapies
The new site enables end-to-end production of viral vector gene therapies
_LOGO_256_384.jpg){kind=logo}
The association called for an end to the constant issuance of regulatory circulars that make operations unpredictable and capital-intensive.
The positive opinion is based on results from KOMET, the largest and only placebo-controlled, double-blind global Phase III trial in this patient population
The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines
Sessions will cover process mapping, cost optimisation, data-driven decision-making, cybersecurity, and sustainable manufacturing practices
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
Pete Pharma will leverage FABRX’s extensive foundation of scientific validation to deliver a commercially viable, pharmacy-ready solution in the US
Subscribe To Our Newsletter & Stay Updated
